EPCAM and lung carcinoma: This suggests that detecting EpCAM+ CTCs and CTECs in post‐therapeutic lung cancer patients is of particular clinical utility, in terms of timely detecting emerging therapeutic resistance and appraising patients’ poor response to combination therapy.